Natus Medical Inc. (NASDAQ:BABY) – Analysts at William Blair dropped their FY2016 EPS estimates for Natus Medical in a research report issued to clients and investors on Tuesday. William Blair analyst B. Weinstein now forecasts that the brokerage will post earnings per share of $1.62 for the year, down from their prior estimate of $1.73. William Blair also issued estimates for Natus Medical’s FY2017 earnings at $1.75 EPS.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.36 by $0.03. The firm had revenue of $96 million for the quarter, compared to analyst estimates of $92.71 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.34 earnings per share.
Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Thursday, July 7th. Raymond James Financial Inc. raised Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 target price on the stock in a research note on Tuesday, September 13th.
Natus Medical (NASDAQ:BABY) opened at 39.04 on Thursday. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of 33.66 and a beta of 0.85. The stock’s 50 day moving average price is $40.39 and its 200 day moving average price is $36.82. Natus Medical has a 52 week low of $29.54 and a 52 week high of $51.05.
In other news, insider James B. Hawkins bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 28th. The shares were purchased at an average price of $38.48 per share, with a total value of $384,800.00. Following the purchase, the insider now owns 459,725 shares in the company, valued at $17,690,218. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.80% of the company’s stock.
Large investors have recently modified their holdings of the company. Clinton Group Inc. increased its stake in shares of Natus Medical by 0.7% in the second quarter. Clinton Group Inc. now owns 8,614 shares of the company’s stock valued at $326,000 after buying an additional 64 shares during the period. PineBridge Investments L.P. increased its stake in shares of Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 149 shares during the period. Suntrust Banks Inc. increased its stake in shares of Natus Medical by 3.7% in the second quarter. Suntrust Banks Inc. now owns 5,776 shares of the company’s stock valued at $218,000 after buying an additional 204 shares during the period. Arizona State Retirement System increased its stake in shares of Natus Medical by 1.8% in the second quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock valued at $650,000 after buying an additional 300 shares during the period. Finally, Invictus RG increased its stake in shares of Natus Medical by 8.7% in the second quarter. Invictus RG now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 336 shares during the period. Institutional investors own 87.92% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.